{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:05:27Z","timestamp":1780085127561,"version":"3.54.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012593","name":"Scientific Research Foundation of Graduate School of Harbin Medical University: Sino Russian Special Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.heliyon.2019.e02033","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T02:13:18Z","timestamp":1562119998000},"page":"e02033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia"],"prefix":"10.1016","volume":"5","author":[{"given":"Anastasiia S.","family":"Boiko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina A.","family":"Mednova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena G.","family":"Kornetova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiy V.","family":"Semke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay A.","family":"Bokhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton J.M.","family":"Loonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana A.","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2019.e02033_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses","volume":"13","author":"Moreno-Kustner","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2019.e02033_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorthoj","year":"2017","journal-title":"Lancet Psychiatr"},{"key":"10.1016\/j.heliyon.2019.e02033_bib3","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jpsychires.2013.07.011","article-title":"Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies","volume":"47","author":"Fan","year":"2013","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.heliyon.2019.e02033_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2013.09.009","article-title":"Metabolic syndrome","volume":"43","author":"Samson","year":"2014","journal-title":"Endocrinol Metab. Clin. N. Am."},{"key":"10.1016\/j.heliyon.2019.e02033_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.heliyon.2019.e02033_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/schbul\/sbs082","article-title":"Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"Suppl 2","key":"10.1016\/j.heliyon.2019.e02033_bib7","first-page":"S94","article-title":"The metabolic syndrome in untreated schizophrenia patients: prevalence and putative mechanisms","volume":"25","author":"Reddy","year":"2013","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.heliyon.2019.e02033_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WNF.0b013e31824d5288","article-title":"Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies","volume":"35","author":"Bou Khalil","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.heliyon.2019.e02033_bib9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","article-title":"Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies","volume":"40","author":"Hirsch","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.heliyon.2019.e02033_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatr."},{"issue":"7","key":"10.1016\/j.heliyon.2019.e02033_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12272-018-1039-x","article-title":"Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives","volume":"41","author":"Liu","year":"2018","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"2","key":"10.1016\/j.heliyon.2019.e02033_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.dsx.2017.11.006","article-title":"Metabolic syndrome in drug na\u00efve schizophrenic patients","volume":"12","author":"Anjum","year":"2018","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.heliyon.2019.e02033_bib13","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/j.1582-4934.2012.01543.x","article-title":"Potential biomarkers in psychiatry: focus on the cholesterol system","volume":"16","author":"Woods","year":"2012","journal-title":"J.\u00a0Cell Mol. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2019.e02033_bib14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0022-2275(20)34443-6","article-title":"Plasma lipoproteins: apolipoprotein structure and function","volume":"25","author":"Mahley","year":"1984","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.heliyon.2019.e02033_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biochi.2013.08.027","article-title":"Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes","volume":"96","author":"Ma\u00efga","year":"2014","journal-title":"Biochimie"},{"key":"10.1016\/j.heliyon.2019.e02033_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2017.10.025","article-title":"Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism","volume":"267","author":"Wolska","year":"2017","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.heliyon.2019.e02033_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: From pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2019.e02033_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-1-4020-8831-5_9","article-title":"Altered lipid metabolism in brain injury and disorders","volume":"49","author":"Adibhatla","year":"2008","journal-title":"Subcell. Biochem."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e02033_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12031-016-0839-z","article-title":"The complex role of apolipoprotein E in Alzheimer's disease: an overview and update","volume":"60","author":"Mahoney-Sanchez","year":"2016","journal-title":"J.\u00a0Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.heliyon.2019.e02033_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.heliyon.2019.e02033_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome--a new world-wide definition. A consensus statement from the international diabetes federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet. Med."},{"key":"10.1016\/j.heliyon.2019.e02033_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/01902148409109252","article-title":"A\u00a0review of plasma apolipoprotein A-I interactions with phosphatidylcholines","volume":"6","author":"Jonas","year":"1984","journal-title":"Exp. Lung Res."},{"key":"10.1016\/j.heliyon.2019.e02033_bib23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/sj.mp.4002108","article-title":"Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues","volume":"13","author":"Huang","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.heliyon.2019.e02033_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ajp.2013.12.019","article-title":"Paraoxonase 1 activity and lipid profile in schizophrenic patients","volume":"9","author":"Mabrouk","year":"2014","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.heliyon.2019.e02033_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0021-9150(84)90164-3","article-title":"Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines","volume":"51","author":"Sasaki","year":"1984","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.heliyon.2019.e02033_bib26","first-page":"1001","article-title":"Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects","volume":"24","author":"Wen","year":"2003","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.heliyon.2019.e02033_bib27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00702-006-0607-2","article-title":"Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients","volume":"114","author":"La","year":"2007","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.heliyon.2019.e02033_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/CCLM.2010.004","article-title":"Inverse relationship between serum high density lipoprotein and negative syndrome in antipsychotic-naive schizophrenia","volume":"48","author":"Venkatasubramanian","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.heliyon.2019.e02033_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fphar.2015.00278","article-title":"Importance of apolipoprotein A-I in multiple sclerosis","volume":"6","author":"Gardner","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2019.e02033_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jneuroim.2014.10.010","article-title":"A\u00a0role for Apolipoprotein A-I in the pathogenesis of multiple sclerosis","volume":"277","author":"Meyers","year":"2014","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.heliyon.2019.e02033_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5507\/bp.2014.060","article-title":"The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review","volume":"159","author":"Kucerova","year":"2015","journal-title":"Biomed. Pap. Med. Fac"},{"issue":"Suppl","key":"10.1016\/j.heliyon.2019.e02033_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0269881111431622","article-title":"The metabolic syndrome in schizophrenia: is inflammation a contributing cause?","volume":"26","author":"Leonard","year":"2012","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.heliyon.2019.e02033_bib33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/ATVBAHA.112.300921","article-title":"Apolipoprotein A-II: still second fiddle in high-density lipoprotein metabolism?","volume":"33","author":"Remaley","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2019.e02033_bib34","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1515\/CCLM.2009.310","article-title":"Impaired anti-inflammatory function of apolipoprotein A-II concentrations predicts metabolic syndrome and diabetes at 4 years follow-up in elderly Turks","volume":"47","author":"Onat","year":"2009","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e02033_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/07853890510007322","article-title":"The double jeopardy of HDL","volume":"37","author":"Navab","year":"2005","journal-title":"Ann. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e02033_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/biof.1205","article-title":"The dual nature of HDL: anti-Inflammatory and pro-Inflammatory","volume":"41","author":"Namiri-Kalantari","year":"2015","journal-title":"Biofactors"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e02033_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1385\/JMN:23:3:205","article-title":"A\u00a0dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity","volume":"23","author":"Guo","year":"2004","journal-title":"J.\u00a0Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e02033_bib38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.ATV.19.3.472","article-title":"Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3","volume":"19","author":"Jong","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2019.e02033_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104833","article-title":"Reduced apolipoprotein glycosylation in patients with the metabolic syndrome","volume":"9","author":"Savinova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2019.e02033_bib40","first-page":"55","article-title":"Predictive value of apolipoprotein for coronary atherosclerosis in asymptomatic non-diabetic population","volume":"37","author":"Song","year":"2015","journal-title":"Zhongguo Yi XueKeXue Yuan XueBao"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844019356932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844019356932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:01:38Z","timestamp":1764320498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844019356932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S2405844019356932"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02033","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e02033"}}